Wonder whether Biogen’s resurrection of aducanumab has stoked unrealistic hopes for Alzheimer’s disease progress? Look no further than Lilly’s shares, which opened 4% down this morning on the failure of the Dian-Tu study, an ambitious trial handicapped by a very small sample size.
Biogen shares were largely unmoved, meanwhile; while a positive signal in Dian-Tu would have been claimed as a major endorsement of the beta-amyloid hypothesis, aducanumab bulls have swiftly pointed to trial design and differences in the antibodies involved. These might be valid points, but yet another setback for this space only emphasises just how precarious Biogen’s position is here.
Dian-Tu was run by Washington University, and tested two failed anti-amyloid beta antibodies, Lilly’s solanezumab and Roche’s gantenerumab, in subjects with a rare inherited form of early-onset dementia called autosomal-dominant Alzheimer's disease (ADAD). Because these individuals display degeneration at a predictable age, researchers hoped to tease out a benefit in a small number of subjects (Another chance for Lilly and Roche to take on Alzheimer's, January 31, 2020).
None was seen, at least according to the primary endpoint of the study: neither project showed a significant slowing of cognitive decline, statements from Lilly and Roche said today. These press releases also confirmed the very small number of patients that received the active agents; 52 were randomised to receive gantenerumab, while only 50 received solanezumab.
The full data, due to be presented at a medical conference in April, remain of interest. The high doses tested in Dian-Tu helped rekindle hopes here, echoing Biogen’s case for finding a way forward for aducanumab: that if you dose patients high enough and long enough, an effect can be seen. But Dian-Tu only hiked the dosages half way through; this, and the very small sample size, will surely render any positive signals to emerge in the full results exploratory at best.
|Important differences? How the amyloid-beta antibodies differ, mechanistically|
|Target||Fibrillar and oligomeric amyloid-beta||Fibrillar and oligomeric amyloid-beta||Soluble monomeric amyloid-beta|
|Epitope||N-terminus (3-7)||N-terminus (3-11) and mid-domain (18-27)||Mid-domain (16-26)|
|Source: sellside research.|
Analysts at SVB Leerink, who only a few weeks ago declared that the Dian-Tu outcome would influence whether confidence in beta-amyloid as a target, and thus Biogen’s antibodies, went up or down, today decided that the outcome had limited impact on aducanumab. The bank has been a major supporter of Biogen’s stance that aducanumab is approvable.
These three anti-beta-amyloid antibodies all work slightly differently, targeting different epitopes, Leerink pointed out. Again, the small number of patients involved here surely means that mechanistic conclusions are hard to draw.
Still, it is hard to escape the notion that Biogen’s putative progress with aducanumab raised unrealistic hopes here. The next big test for this mechanism will probably come from Roche’s gantenerumab, which is due to complete a prodromal study later this year, and Biogen bulls will no doubt be ready with reasons should this fail too.
|Selected upcoming Alzheimer's disease readouts|
|Roche||gantenerumab||Anti-beta-amyloid MAb||NCT01224106||Prodromal (phase III)||Mid-2020|
|Roche/AC Immune||Semorinemab (RG6100)||Anti-Tau MAb||NCT03289143||Prodromal/Mild AD ( phase II)||Mid-2020|
|Biohaven||troriluzole||Glutamate modulator||NCT03605667||Mild-to-moderate AD (phase II/III||Late 2020|
|Eli Lilly||Donanemab (LY3002813)||N3PG antibody||Trailblazer-Alz NCT03367403||Early symptomatic AD (phase II)||Late 2020|
|Cortexyme||COR388||Gingipain inhibitor||Gain NCT03823404||Mild to moderate AD (phase II/III)||Poss interim analysis mid/late 2020; completion late 2021.|
|Abbvie||ABBV-8E12||Anti-Tau MAb||NCT02880956||Early AD (phase II)||2020 (primary completion Apr 2021)|
|Roche||gantenerumab||Anti-beta-amyloid MAb||NCT02051608||Mild AD (phase III)||Q2 2021|
|Biogen||Gosuranemab (BIIB-092)||Anti-Tau MAb||Tango NCT03352557||Early AD (phase II)||2021|
|Lilly||Zagotenemab (LY3303560)||Anti-Tau MAb||NCT03518073||Early symptomatic AD (phase II)||2021|
|Source: EvaluatePharma & company statements.|